We have reported that IGFBP-2 can promote prostate tumour progression by acting as a growth promoter, a survival factor against docetaxel-induced cell death [17] and that hyperglycaemia-induced up-regulation of IGFBP-2 conferred chemo-resistance in prostate cancer cells [18]. This evidence concerns the gene IGFBP2 and prostate carcinoma.